Jasper Therapeutics, Inc. JSPR stock is experiencing a steep decline on Monday, plummeting by nearly 55%. This significant drop is accompanied by an exceptionally high trading volume of 9.9 million shares, vastly exceeding its average daily volume of 251.9K, according to data from Benzinga Pro.What Happened?The company reported updated data from the BEACON Phase 1b/2a study of subcutaneous briquilimab in adult chronic spontaneous urticaria (CSU) participants and provided an update on the program. It reporte ...